Insider Selling: Scholar Rock Holding Co. (NASDAQ:SRRK) Director Sells 3,375 Shares of Stock

Scholar Rock Holding Co. (NASDAQ:SRRK - Get Free Report) Director Michael Gilman sold 3,375 shares of the stock in a transaction dated Thursday, May 29th. The stock was sold at an average price of $29.72, for a total value of $100,305.00. Following the transaction, the director now directly owns 55,216 shares in the company, valued at approximately $1,641,019.52. The trade was a 5.76% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Scholar Rock Stock Up 0.7%

SRRK stock traded up $0.21 during mid-day trading on Monday, reaching $29.22. The company had a trading volume of 164,220 shares, compared to its average volume of 1,265,774. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88. The company has a market capitalization of $2.77 billion, a price-to-earnings ratio of -12.50 and a beta of 0.37. The firm has a fifty day simple moving average of $30.38 and a 200 day simple moving average of $36.10. Scholar Rock Holding Co. has a fifty-two week low of $6.76 and a fifty-two week high of $46.98.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.04). During the same quarter in the prior year, the business earned ($0.59) earnings per share. Analysts forecast that Scholar Rock Holding Co. will post -2.42 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Scholar Rock

A number of hedge funds have recently bought and sold shares of the stock. Rhumbline Advisers raised its position in Scholar Rock by 6.6% in the 1st quarter. Rhumbline Advisers now owns 120,752 shares of the company's stock valued at $3,882,000 after purchasing an additional 7,491 shares in the last quarter. Strs Ohio purchased a new position in shares of Scholar Rock in the 1st quarter valued at about $77,000. Intech Investment Management LLC increased its holdings in shares of Scholar Rock by 60.9% in the 1st quarter. Intech Investment Management LLC now owns 56,784 shares of the company's stock valued at $1,826,000 after acquiring an additional 21,483 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Scholar Rock by 25.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 169,825 shares of the company's stock valued at $5,460,000 after acquiring an additional 34,594 shares during the last quarter. Finally, Exome Asset Management LLC increased its holdings in shares of Scholar Rock by 8.9% in the 1st quarter. Exome Asset Management LLC now owns 84,339 shares of the company's stock valued at $2,711,000 after acquiring an additional 6,900 shares during the last quarter. Institutional investors and hedge funds own 91.08% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Wedbush reissued an "outperform" rating and set a $50.00 target price on shares of Scholar Rock in a research note on Wednesday, May 14th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $42.67.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.